Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial

David J Gagnon, Sergey V Ryzhov, Meghan A May, Richard R Riker, Bram Geller, Teresa L May, Sarah Bockian, Joanne T deKay, Ashley Eldridge, Thomas Van der Kloot, Patricia Lerwick, Christine Lord, F Lee Lucas, Patrick Mailloux, Barbara McCrum, Meghan Searight, Joel Wirth, Jonathan Zuckerman, Douglas Sawyer, David B Seder, David J Gagnon, Sergey V Ryzhov, Meghan A May, Richard R Riker, Bram Geller, Teresa L May, Sarah Bockian, Joanne T deKay, Ashley Eldridge, Thomas Van der Kloot, Patricia Lerwick, Christine Lord, F Lee Lucas, Patrick Mailloux, Barbara McCrum, Meghan Searight, Joel Wirth, Jonathan Zuckerman, Douglas Sawyer, David B Seder

Abstract

Background: Pneumonia is the most common infection after out-of-hospital cardiac arrest (OHCA) occurring in up to 65% of patients who remain comatose after return of spontaneous circulation. Preventing infection after OHCA may (1) reduce exposure to broad-spectrum antibiotics, (2) prevent hemodynamic derangements due to local and systemic inflammation, and (3) prevent infection-associated morbidity and mortality.

Methods: The ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arrest (PROTECT) trial is a randomized, placebo-controlled, single-center, quadruple-blind (patient, treatment team, research team, outcome assessors), non-commercial, superiority trial to be conducted at Maine Medical Center in Portland, Maine, USA. Ceftriaxone 2 g intravenously every 12 h for 3 days will be compared with matching placebo. The primary efficacy outcome is incidence of early-onset pneumonia occurring < 4 days after mechanical ventilation initiation. Concurrently, T cell-mediated inflammation bacterial resistomes will be examined. Safety outcomes include incidence of type-one immediate-type hypersensitivity reactions, gallbladder injury, and Clostridioides difficile-associated diarrhea. The trial will enroll 120 subjects over approximately 3 to 4 years.

Discussion: The PROTECT trial is novel in its (1) inclusion of OHCA survivors regardless of initial heart rhythm, (2) use of a low-risk antibiotic available in the USA that has not previously been tested after OHCA, (3) inclusion of anti-inflammatory effects of ceftriaxone as a novel mechanism for improved clinical outcomes, and (4) complete metagenomic assessment of bacterial resistomes pre- and post-ceftriaxone prophylaxis. The long-term goal is to develop a definitive phase III trial powered for mortality or functional outcome.

Trial registration: ClinicalTrials.gov NCT04999592 . Registered on August 10, 2021.

Keywords: Antibiotics; Cardiac arrest; Ceftriaxone; Hypothermia; Inflammation; Metagenomics; Microbiome; Pneumonia; Targeted temperature management.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Ceftriaxone increases CD73 on T lymphocytes, and CD73 levels correlate with IFN-γ. A T cells were purified from peripheral blood from pre-operative coronary artery bypass patients and incubated in the absence (control) or presence of 50 μg/ml ceftriaxone for 24 h. B CD73 was measured in viable CD3 T cells gated as shown (red gate). C Quantification of flow cytometric data showing CD73 in total CD3 T cells and subpopulations of CD4+ and CD8+ unpaired t test, n=4. D Subpopulations of peripheral blood cells. E CD3+ T lymphocytes were gated and subpopulations of CD4+ (blue gate) and CD8+ (red gate) identified (F). G, H The expression of CD73 and production of IFN-γ in subpopulations of CD4+ (blue gate) and CD8+ (red gate) T lymphocytes

References

    1. Rello J, Emili D. Pneumonia in the intensive care unit. Crit Care Med. 2003;31:2544–2551.
    1. Perbet S, Mongardon N, Dumas F, et al. Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis. Am J Respir Crit Care Med. 2011;184:1048–1054.
    1. Gajic O, Festic E, Afessa B. Infectious complications in survivors of cardiac arrest admitted to the medical intensive care unit. Resuscitation. 2004;60:65–69.
    1. Rello J, Vallés J, Jubert P, et al. Lower respiratory tract infections following cardiac arrest and cardiopulmonary resuscitation. Clin Infect Dis. 1995;21:310–314.
    1. Gaussorgues P, Gueugniaud PY, Vedrinne JM, Salord F, Mercatello A, Robert D. Bacteremia following cardiac arrest and cardiopulmonary resuscitation. Intensive Care Med. 1988;14:575–577.
    1. Kim YM, Youn CS, Kim SH, et al. Adverse events associated with poor neurological outcome during targeted temperature management and advanced critical care after out-of-hospital cardiac arrest. Crit Care. 2015;19:283.
    1. Bjork RJ, Snyder BD, Campion BC, Loewenson RB. Medical complications of cardiopulmonary arrest. Arch Intern Med. 1982;142:500–503.
    1. Voorhees WD, Babbs CF, Tacker WA., Jr Regional blood flow during cardiopulmonary resuscitation in dogs. Crit Care Med. 1980;8(3):134–136.
    1. Grimaldi D, Guivarch E, Neveux N, et al. Markers of intestinal injury are associated with endotoxemia in successfully resuscitated patients. Resuscitation. 2013;84(1):60–65.
    1. Grimaldi D, Sauneuf B, Guivarch E, et al. High level of endotoxemia following out-of-hospital cardiac arrest is associated with severity and duration of postcardiac arrest shock. Crit Care Med. 2015;43:2597–2504.
    1. Adrie C, Laurent I, Monchi M, Cariou A, Dhainaou JF, Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Curr Opin Crit Care. 2004;10:208–212.
    1. Adrie C, Adib-Conquy M, Laurent I, et al. Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation. 2002;106:562–568.
    1. Soppi E, Lindroos M, Nikoskelainen J, Kalliomäki JL. Effect of cardiopulmonary resuscitation-induced stress on cell-mediated immunity. Intensive Care Med. 1984;10:287–292.
    1. Beurskens CJ, Horn J, de Boer AM, Schultz MJ, van Leeuwen EM, Vroom MB, Juffermans NP. Cardiac arrest patients have an impaired immune response, which is not influenced by induced hypothermia. Crit Care. 2014;18:R162.
    1. Sirvent JM, Torres A, El-Ebiary M, Castro P, de Batlle J, Bonet A. Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. Am J Respir Crit Care Med. 1997;155:1729–1734.
    1. Acquarolo A, Urli T, Perone G, Giannotti C, Candiani A, Latronico N. Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study. Intensive Care Med. 2005;31:510–516.
    1. Vallés J, Peredo R, Burgueño MJ, et al. Efficacy of single-dose antibiotic against early-onset pneumonia in comatose patients who are ventilated. Chest. 2013;143:1219–1225.
    1. François B, Cariou A, Clere-Jehl R, et al. Prevention of early ventilator-associated pneumonia after cardiac arrest. N Engl J Med. 2019;381:1831–1842.
    1. Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors Exception from Informed Consent Requirements for Emergency Research . Food and Drug Administration. 2013.
    1. Ceftriaxone [package insert]. Weston, FL: Apotex Corporation; 2011.
    1. Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33 °C vs. 36 °C after cardiac arrest. N Engl J Med. 2013;369:2197–2206.
    1. Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. 2021;384:2283–2294.
    1. Skrupky LP, McConnell K, Dallas J, Kollef MH. A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians Criteria. Crit Care Med. 2012;40:281–284.
    1. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
    1. McDonald CL, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) Clin Infect Dis. 2018;66:e1–e48.
    1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117:391–397.
    1. Harmon MBA, Hodiamont CJ, Dankiewicz J, et al. Microbiological profile of nosocomial infections following cardiac arrest: Insights from the targeted temperature management (TTM) trial. Resuscitation. 2020;148:227–233.
    1. The International Cardiac Arrest Registry. Maine Medical Center Research institute, Scarborough, Maine. 2021. . Accessed May 3, 2021.
    1. Russell JA, Epstein LG, Greer DM, et al. Brain death, the determination of brain death, and member guidance for brain death accommodation requests. Neurology. 2019;92:228–304.
    1. Zerbino DR, Birney E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 2008;18:821–829.
    1. Gibson MK, Forsberg KJ, Dantas G. Improved annotation of antibiotic resistance determinants reveals microbial resistomes cluster by ecology. ISME J. 2015;9:207–216.
    1. Kaminski J, Gibson MK, Franzosa EA, et al. High-specificity targeted functional profiling in microbial communities with ShortBRED. PLoS Comput Biol. 2015;11:e1004557.
    1. Ryzhov SV, Pickup MW, Chytil A, et al. Role of TGF-beta signaling in generation of CD39+CD73+ myeloid cells in tumors. J Immunol. 2014;193:3155–3164.
    1. Wei J, Pan X, Pei Z, et al. The beta-lactam antibiotic, ceftriaxone, provides neuroprotective potential via anti-excitotoxicity and anti-inflammation response in a rat model of traumatic brain injury. The J Trauma Acute Care Surg. 2012;73:654–660.
    1. Melzer N, Meuth SG, Torres-Salazr D, et al. A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS One. 2008;3:e3149.
    1. Hameed MQ, Hsieh TH, Morales-Quezada L, et al. Ceftriaxone treatment preserves cortical inhibitory interneuron function via transient salvage of GLT-1 in a rat traumatic brain injury model. Cereb Cortex. 2019;29:4506–4518.
    1. Krzyzanowska W, Pomierny B, Bystrowska B, et al. Ceftriaxone- and N-acetylcysteine-induced brain tolerance to ischemia: Influence on glutamate levels in focal cerebral ischemia. PLoS One. 2017;12:e0186243.
    1. Jagadapillai R, Mellen NM, Sachleben LR, Jr, Gozal E. Ceftriaxone preserves glutamate transporters and prevents intermittent hypoxia-induced vulnerability to brain excitotoxic injury. PLoS One. 2014;9:e100230.
    1. Hu YY, et al. Ceftriaxone modulates uptake activity of glial glutamate transporter-1 against global brain ischemia in rats. J Neurochem. 2015;132:194–205.
    1. Tai CH, Bellesi M, Chen AC, et al. A new avenue for treating neuronal diseases: Ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects. Behav Brain Res. 2019;364:149–156.
    1. Gonzalez H, Pacheco R. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. Journal of Neuroinflammation. 2014;11:201.
    1. Daglas M, Draxler DF, Ho H, et al. Activated CD8+ T cells cause long-term neurological impairment after traumatic brain injury in mice. Cell Reports. 2019;29:1178–1191.e1176.
    1. Clemenzi MN, Wellhauser L, Aljghami ME, Belsham DD. Tumour necrosis factor α induces neuroinflammation and insulin resistance in immortalised hypothalamic neurones through independent pathways. J Neuroendocrinol. 2019;31:e12678.
    1. Van Puyvelde S, Deborggraeve S, Jacobs J. Why the antibiotic resistance crisis requires a One Health approach. Lancet Infect Dis. 2018;18:132–134.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi